BELLUS Health Inc (BLU)

[Necropolis]

July 15, 2020 From the Daily Bio-tech Pulse Moderna (Nasdaq:$MRNA) and Bluth (NYSE:$BLU) have partnered up the Possible Moderna Vaccine Moderna announced in the New England journal of medicine a detailed interim of phase 1 data for its mRNA-1273 Vaccine candidate against the novel corona virus, showing the vaccine candidate induced rapid and strong immune responses the vaccine candidate induced binding Anti-bodies to the full -length SARS-CoViD-02 virus in all participants in the study after the first vaccination with all the participants starting to show signs of recovery by day 15 the company said , these Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly supports the choice on July 15 for the decision to go ahead for the phase 3 study on July 27 said by Tal Zaks the Chief Medical Officer (CMO) of Moderna Inc... Moderna expects to commence the phase 3 study on July 27
$MRNA is up 16% since the news, $BLU is up 8% since the July 15 news of the Phase 3 trial coming on Monday July 27, the stock could pop on Monday from the hype also the chart looks good for daily indicators so people should buy the stock and make gains on this BLU stock and this exciting corona virus vaccine news.